aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting
11 mars 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor
10 mars 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Present at March Investor Conferences
25 févr. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces New tRNA Synthetase Discovery Programs
11 févr. 2021 08h00 HE
|
aTyr Pharma, Inc.
Advancement of selected AARS and DARS fragments primarily targeting cancer Programs will accelerate discoveries initially focusing on natural killer (NK) cell biology SAN DIEGO , Feb. 11, 2021 ...
aTyr Pharma to Present at BIO CEO & Investor Digital Conference
09 févr. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression
25 janv. 2021 08h00 HE
|
aTyr Pharma, Inc.
Poster highlights NRP2 expression on immune cells in the tumor microenvironment. Company's lead NRP2 antibody, ATYR2810, is in development for oncology. SAN DIEGO, Jan. 25, 2021 ...
aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases
22 janv. 2021 08h00 HE
|
aTyr Pharma, Inc.
Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition. Research approach led to the identification of target receptors for...
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan
14 janv. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
07 janv. 2021 07h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
04 janv. 2021 16h15 HE
|
aTyr Pharma, Inc.
Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients. A single dose of 3.0 mg/kg of ATYR1923 resulted in a median time to recovery of 5.5 days. 83% of patients...